Specialty Pharmacy

Turnover from novel therapeutic target to model systems in clinical use remains a challenge.

Catch up with the latest news in cancer research.

Research may lead to alternative treatment options.

A number of barriers found in smoking cessation.

About 96% of online pharmacies are noncompliant with federal and state laws or National Association of Boards of Pharmacy (NABP) safety and pharmacy practice standards.

Combining chemotherapy with immune blocker could prevent cancer from growing back.

A look back at the top stories of the week on Specialty Pharmacy Times.

Compound kills breast, prostate, lung, and liver cancer cells without harming healthy cells.

Study suggests rheumatoid arthritis chronicity can be influenced.

Research could aid drug discovery.

Bill authorizes the VA to spend as much as $500 million for hepatitis C treatments.

For more than 25 years, the Midwest AIDS Training + Education Center has educated clinicians who provide care to patients infected with human immunodeficiency virus (HIV) and those at risk for HIV.

Intra-abdominal fat cells associated with the progression of Crohn's disease and ulcerative colitis.

Molecular partnership may generate much-needed new treatments for the disease.

Cost of premiums, deductibles, and copays listed as important factors in choosing health plans.

Agreement with Immune Design could expand the potential of immunotherapy through combination approaches.

Onsolis provides opioid tolerant patients with an alternative dosing option.

Compound targets latent HIV proteins without harming other parts of the body.

Drug reduced chorea and writhing movements in patients afflicted with the disease.

Ethicists worried trials will threaten scientific rigor and efficacy.

Screening evaluates a large number of cells used in cancer therapy.

States need to target specific populations affected by HIV outbreaks.

Research advances personalized cancer therapy.

Alliances with specialty pharmacies result in collaboration and knowledge exchange, while building trust and increasing visibility of partners' services.

Religion and spirituality can have a positive impact on cancer outcomes.

MS comorbidities increase the risk of early mortality.

FDA-approved drug is now a first-line treatment for select patients with EGFR non-small cell lung cancer.

New treatment approach many help control inflammation.